Regulatory Approvals of Novel Therapies Drive the Liver Cancer Treatment Market Growth

Liver cancer treatment market was valued at $4,920 million in 2025 and is projected to reach $14,400 million by 2035, growing at a CAGR of 11.4% during the forecast period (2026-2035). The rapid approvals of immunotherapy combinations, liver-directed therapies, and metabolic-related treatments are enhancing the treatment landscape and driving market growth. For instance, in April 2025, the FDA approved the combination of nivolumab with ipilimumab for first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma. CHECKMATE-9DW trial assessed the efficacy of nivolumab in 668 adults with unresectable or metastatic HCC. Patients were administered intravenous nivolumab 1 mg/kg, ipilimumab 3 mg/kg IV every 3 weeks, single agent nivolumab 480 mg IV every 4 weeks, or lenvatinib or sorafenib.

Browse the full report description of “Liver Cancer Treatment Market Size, Share & Trends Analysis Report by Cancer Type (Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Hepatoblastoma, Fibrolamellar Carcinoma, and Others) by Source (Synthetic, and Natural) and by Therapy Type (Targeted Therapy, Immunotherapy, Chemotherapy, Radiation Therapy, and Surgical Interventions) Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/liver-cancer-treatment-market

Recent FDA Approvals Transforming the Global Liver Cancer Treatment Market

• In August 2025, the FDA approved Wegovy (semaglutide) injection for the treatment of metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis. MASH, also referred to as nonalcoholic steatohepatitis, is a severe liver disease occurring in 6% of US adults and rising in prevalence. The injection is also approved for obesity and high-risk patients to lower cardiovascular events. MASH can progress to cirrhosis, liver cancer, liver transplant, or mortality.
• In July 2025, the FDA approved SIR-Spheres Y-90 resin microspheres for the treatment of unresectable hepatocellular carcinoma (HCC) in the US the first radioembolization therapy approved in the US for both metastatic colorectal cancer and HCC This broadens clinicians' options to select a liver-directed therapy best suited to each patient's individual needs and objectives.
• In April 2025, the US Food and Drug Administration (FDA) approved the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line therapy for patients with unresectable or metastatic hepatocellular carcinoma (HCC). The Phase 3 CheckMate-9DW trial reflected a meaningful benefit in overall survival against lenvatinib or sorafenib. The treatment had better outcomes than the comparator arm, as 38% of the patients remained alive at 3 years.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Cancer Type
  • By Therapy Type
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Bayer AG, Bristol-Myers Squibb Co., Eisai Inc., AstraZeneca, Exelixis, Inc., F. Hoffmann-La Roche Ltd., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Liver Cancer Treatment Market Report Segment

By Cancer Type

• Hepatocellular Carcinoma (HCC)
• Cholangiocarcinoma
• Hepatoblastoma
• Fibrolamellar Carcinoma
• Others (Angiosarcoma of the Liver)

By Application

• Targeted Therapy
• Immunotherapy
• Chemotherapy
• Radiation Therapy
• Surgical Interventions

Global Liver Cancer Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/liver-cancer-treatment-market